Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Gain-of-function BRAF mutations are common in melanoma, leading to dependence on the RAF-MEK-ERK signaling pathway.
• While RAF and MEK inhibitors are effective, drug resistance frequently arises due to MAPK pathway reactivation.

Purpose of the Study:

• To investigate the consequences of MAPK pathway hyperactivation in melanoma.
• To identify mechanisms and mediators involved in MAPK hyperactivation-induced cell death.

Main Methods:

• Generated isogenic models of inducible MAPK hyperactivation via ERK2 overexpression in BRAFV600E melanoma cells.
• Conducted a pooled shRNA screen to identify genes mediating cell death.
• Analyzed secreted proteins in response to MAPK hyperactivation.

Main Results:

• Supraphysiologic MAPK signaling induced cell death, reversed by MAPK inhibition.
• ERK2 overexpression led to complete tumor regression in a xenograft model.
• shRNA screening identified BRAF and MAP2K1 as essential for viability, indicating pleiotropic effects.
• Over 100 differentially secreted proteins were identified.
• Sensitivity to MAPK hyperactivation was context-dependent, observed in RAS/RAF-mutant but not wild-type melanoma.

Conclusions:

• MAPK pathway hyperactivation triggers cell death in specific melanoma contexts.
• This vulnerability presents a potential therapeutic target for RAS/RAF-mutant cancers.
• The findings suggest complex downstream effects and secreted factors mediate the response to MAPK hyperactivation.